How mTor blocks Experimental Cerebral Malaria
Malaria is a life-threatening disease caused by Plasmodium parasites that are transmitted to people through the bites of infected mosquitoes. The parasites are spread to people through the bites of infected Anopheles mosquitoes, called “malaria vectors“, which bite mainly between dusk and dawn.
There are four parasite species that cause malaria in humans:
- Plasmodium falciparum
- Plasmodium vivax
- Plasmodium malariae
- Plasmodium ovale.
Cerebral Malaria (CM) is a common form of severe malaria and it is one of the commonest and most important complication of P. falciparum. Signs and symptoms in children are: convulsions, respiratory distress, prostration, invasive bacterial infection and neurological sequelae after cerebral malaria.
A new study published on the online journal mBio last 2nd June shows how the inhibition of the kinase mammalian target of rapamycin (mTOR) is able to block the development of Experimental Cerebral Malaria even though rapamycin treatment significantly increased the inflammatory response induced by infection in both the brain and spleen.
Scientists proved by animal experiments that the mTOR inhibitor rapamycincan induce marked transcriptional changes in the brains of infected mice, protecting them against CM if administered within the first 4 days of infection.
According to researchers this work can be considered an important step towards the discovering of a new therapy for CM.
Full Study here
More about Severe Malaria treatment here
Futher information about Malaria here